公开(公告)号：US20220112287A1

公开(公告)日：2022-04-14

申请号：US17559935

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Jenny Jianlin CHEN ,  Tahamtan AHMADI ,  Christopher W.L. CHIU ,  Esther C.W. BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/28

Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

公开(公告)号：US20220088191A1

公开(公告)日：2022-03-24

申请号：US17053753

申请日：2019-05-07

Applicant: Genmab A/S ,  MSD International GmbH

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: A61K39/395 ,  A61K47/68 ,  A61P35/00

Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US20210402003A1

公开(公告)日：2021-12-30

申请号：US17289616

申请日：2019-10-28

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Sandra VERPLOEGEN ,  Esther C.W. BREIJ ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/22 ,  C07K16/36 ,  A61K9/00 ,  A61K45/06 ,  A61K39/395

Abstract: The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.

公开(公告)号：US20210015939A1

公开(公告)日：2021-01-21

申请号：US16982008

申请日：2019-03-20

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO

IPC: A61K47/68 ,  A61P35/00 ,  A61K31/555 ,  A61K9/00

Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.